SEC Comment Letter 0000000000-22-012340 to Akoya Biosciences, Inc. (AKYA) (CIK 0001711933)
Akoya Biosciences, Inc. (AKYA) (CIK 0001711933)
Date: Nov. 14, 2022 · CIK: 0001711933 · Accession: 0000000000-22-012340
AI Filing Summary & Sentiment
File numbers found in text: 333-268214
Letter
United States securities and exchange commission logo November 14, 2022 Brian McKelligon Chief Executive Officer Akoya Biosciences, Inc. 100 Campus Drive, 6th Floor Marlborough, MA 01752 Re:Akoya Biosciences, Inc. Registration Statement on Form S-3 Filed November 7, 2022 File No. 333-268214 Dear Brian McKelligon: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Benjamin Richie at 202-551-7857 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Patrick J. O'Malley, Esq.
Show Raw Text
United States securities and exchange commission logo
November 14, 2022
Brian McKelligon
Chief Executive Officer
Akoya Biosciences, Inc.
100 Campus Drive, 6th Floor
Marlborough, MA 01752
Re:Akoya Biosciences, Inc.
Registration Statement on Form S-3
Filed November 7, 2022
File No. 333-268214
Dear Brian McKelligon:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Benjamin Richie at 202-551-7857 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Patrick J. O'Malley, Esq.